RU2009148270A - Молекулы антител человека к il-13 - Google Patents
Молекулы антител человека к il-13 Download PDFInfo
- Publication number
- RU2009148270A RU2009148270A RU2009148270/10A RU2009148270A RU2009148270A RU 2009148270 A RU2009148270 A RU 2009148270A RU 2009148270/10 A RU2009148270/10 A RU 2009148270/10A RU 2009148270 A RU2009148270 A RU 2009148270A RU 2009148270 A RU2009148270 A RU 2009148270A
- Authority
- RU
- Russia
- Prior art keywords
- group
- amino acid
- acid sequence
- seq
- domain
- Prior art date
Links
- 102000003816 Interleukin-13 Human genes 0.000 title claims 9
- 108090000176 Interleukin-13 Proteins 0.000 title claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 58
- 238000000034 method Methods 0.000 claims abstract 21
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 claims abstract 11
- 230000027455 binding Effects 0.000 claims abstract 11
- 102000019207 human interleukin-13 Human genes 0.000 claims abstract 11
- 239000000427 antigen Substances 0.000 claims abstract 7
- 102000036639 antigens Human genes 0.000 claims abstract 7
- 108091007433 antigens Proteins 0.000 claims abstract 7
- 150000001413 amino acids Chemical class 0.000 claims abstract 5
- 238000006467 substitution reaction Methods 0.000 claims abstract 4
- 238000007792 addition Methods 0.000 claims abstract 3
- 238000012217 deletion Methods 0.000 claims abstract 3
- 230000037430 deletion Effects 0.000 claims abstract 3
- 238000003780 insertion Methods 0.000 claims abstract 3
- 230000037431 insertion Effects 0.000 claims abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 32
- 230000009870 specific binding Effects 0.000 claims 32
- 229910052717 sulfur Inorganic materials 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 229910052740 iodine Inorganic materials 0.000 claims 14
- 229910052727 yttrium Inorganic materials 0.000 claims 9
- 229910052805 deuterium Inorganic materials 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 229910052722 tritium Inorganic materials 0.000 claims 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 208000017604 Hodgkin disease Diseases 0.000 claims 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims 4
- 201000010105 allergic rhinitis Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 238000002703 mutagenesis Methods 0.000 claims 1
- 231100000350 mutagenesis Toxicity 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48751203P | 2003-07-15 | 2003-07-15 | |
| US60/487,512 | 2003-07-15 | ||
| US55821604P | 2004-03-31 | 2004-03-31 | |
| US60/558,216 | 2004-03-31 | ||
| GB0407315.1 | 2004-03-31 | ||
| US57379104P | 2004-05-24 | 2004-05-24 | |
| US60/573,791 | 2004-05-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006104618/13A Division RU2387667C2 (ru) | 2003-07-15 | 2004-07-15 | Молекулы антител человека к il-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009148270A true RU2009148270A (ru) | 2011-06-27 |
Family
ID=44535047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009148270/10A RU2009148270A (ru) | 2003-07-15 | 2009-12-24 | Молекулы антител человека к il-13 |
Country Status (8)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201811177SA (en) * | 2014-06-18 | 2019-01-30 | Medimmune Llc | Cell culture methods and media comprising n-acetylcysteine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07508179A (ja) * | 1992-08-21 | 1995-09-14 | シェリング・コーポレーション | ヒトインターロイキン−１３ |
| JP2005512522A (ja) * | 2001-10-26 | 2005-05-12 | セントカー・インコーポレーテツド | Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用 |
| ES2384100T3 (es) * | 2001-12-03 | 2012-06-29 | Alexion Pharmaceuticals, Inc. | Método para producir anticuerpos híbridos |
| AU2003223497A1 (en) * | 2002-04-05 | 2003-10-27 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| EP1534323A2 (en) * | 2002-08-30 | 2005-06-01 | Glaxo Group Limited | Il-14 vaccine for the treatment of asthma and atopic disorders |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
-
2004
- 2004-07-15 MX MXPA06000258A patent/MXPA06000258A/es active IP Right Grant
- 2004-07-15 KR KR1020067000933A patent/KR101073590B1/ko not_active Expired - Lifetime
-
2006
- 2006-02-15 NO NO20060730A patent/NO338853B1/no unknown
-
2009
- 2009-12-24 RU RU2009148270/10A patent/RU2009148270A/ru not_active Application Discontinuation
-
2011
- 2011-01-25 AU AU2011200308A patent/AU2011200308B2/en not_active Expired
- 2011-04-07 JP JP2011085689A patent/JP5519567B2/ja not_active Expired - Lifetime
- 2011-05-16 CY CY20111100456T patent/CY1111467T1/el unknown
-
2014
- 2014-02-05 JP JP2014020292A patent/JP5922686B2/ja not_active Expired - Lifetime
-
2015
- 2015-12-08 JP JP2015239450A patent/JP2016047843A/ja active Pending
-
2016
- 2016-04-19 HK HK16104446.4A patent/HK1216427A1/zh unknown
- 2016-04-27 NO NO20160707A patent/NO342727B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5922686B2 (ja) | 2016-05-24 |
| KR101073590B1 (ko) | 2011-10-14 |
| NO338853B1 (no) | 2016-10-24 |
| JP2016047843A (ja) | 2016-04-07 |
| AU2011200308A1 (en) | 2011-02-17 |
| HK1216427A1 (zh) | 2016-11-11 |
| NO342727B1 (no) | 2018-07-30 |
| KR20060054312A (ko) | 2006-05-22 |
| AU2011200308B2 (en) | 2011-07-28 |
| CY1111467T1 (el) | 2015-08-05 |
| HK1097853A1 (en) | 2007-07-06 |
| NO20160707A1 (no) | 2016-04-27 |
| JP2011147454A (ja) | 2011-08-04 |
| JP5519567B2 (ja) | 2014-06-11 |
| JP2014101372A (ja) | 2014-06-05 |
| NO20060730L (no) | 2006-04-10 |
| MXPA06000258A (es) | 2006-07-03 |
| HK1155185A1 (en) | 2012-05-11 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20141209 |